Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[tjguy]

The market for immuno-oncology treatments is believed to become worth $14 billion by 2019 and to grow to $34 billion by 2024, driven by long-term and durable tumor responses to immuno-oncology drugs, according to Global Data.

That's great but immuno-oncology is notoriously difficult. I'm going to trust the company that they sufficiently researched this and are not throwing away the profits from a sure thing for hoped for success in a difficult field. That would not make sense to me and I doubt they would do that so we'll have to wait for further explanation from them as to why they chose this particular company and their prospective treatment/approach. If it works, sure, it's BIG bucks. It looks like they are betting it will work.

I'll wait for their explanation and probably hang on for the ride.